
|Articles|March 1, 2004
CMS expands coverage for OPT with verteporfin
Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
ChatGPT-5 overestimates macular hole surgery success, study finds
5


























